Details for Patent: 8,785,632

Which drugs does patent 8,785,632 protect, and when does it expire?

Patent 8,785,632 protects XALKORI and is included in two NDAs.

This patent has fifty-three patent family members in forty-five countries.

Summary for Patent: 8,785,632

Title:	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Abstract:	Enantiomerically pure compound of formula 1 ##STR00001## are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
Inventor(s):	Cui; Jingrong Jean (San Diego, CA), Funk; Lee Andrew (Oceanside, CA), Jia; Lei (San Diego, CA), Kung; Pei-Pei (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA)
Assignee:	Agouron Pharmaceuticals, Inc. (San Diego, CA) Pfizer Inc. (New York, NY)
Application Number:	13/537,759
Patent Claim Types: see list of patent claims	Compound;

Understanding the Scope and Claims of United States Patent 8,785,632

Introduction

United States Patent 8,785,632, titled "Enantiomerically Pure Aminoheteroaryl Compounds as Protein Kinase Inhibitors," is a significant patent in the field of pharmaceuticals, particularly in the development of cancer treatments. Here, we will delve into the details of this patent, including its scope, claims, and the broader patent landscape.

Background of the Patent

This patent, issued on July 22, 2014, is a continuation of earlier applications and is assigned to Agouron Pharmaceuticals, Inc., and Pfizer Inc.[1][4].

Scope of the Patent

The patent focuses on novel chemical compounds, specifically enantiomerically pure aminoheteroaryl compounds, such as aminopyridines and aminopyrazines. These compounds are designed to inhibit protein tyrosine kinases, which are enzymes involved in the regulation of cell growth and division. The preferred compounds are c-Met inhibitors, which are useful for treating abnormal cell growth, including various types of cancers[1][4].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

• Compound Claims: The patent claims enantiomerically pure aminoheteroaryl compounds of specific formulas, highlighting their structural characteristics and stereochemistry[1][4].
• Synthesis Methods: It includes methods for synthesizing these compounds, detailing the chemical reactions and conditions necessary to produce them[1][4].
• Use Claims: The patent claims the use of these compounds as inhibitors of protein tyrosine kinases, particularly c-Met, for the treatment of cancers and other diseases related to abnormal cell growth[1][4].

Patent Landscape

Related Patents

The patent is part of a larger family of patents related to protein kinase inhibitors. Other relevant patents include:

• Patent 7,230,098: This patent, also related to c-Met inhibitors, is set to expire on August 26, 2025[2][5].
• Patent 7,825,137: Another patent in this series, it is scheduled to expire on May 12, 2027[2][5].
• Patent 7,858,643: This patent, which claims the benefit of earlier applications, will expire on October 8, 2029[2][5].
• Patent 8,217,057: This patent, issued to Cui Jingrong Jean and Tran-Dubé Michelle Bich, is related to polymorphs of a c-MET/HGFR inhibitor and is set to expire on November 6, 2029[2][5].

Expiration Dates

The patent US 8,785,632 is scheduled to expire on March 1, 2025. This expiration date is crucial as it will allow generic versions of the drug to enter the market, potentially reducing costs and increasing accessibility[5].

Impact on Pharmaceutical Industry

Innovation and Competition

The expiration of this patent and related ones will open up the market for generic competitors, which can lead to increased competition and potentially lower drug prices. However, it also means that the original patent holders will lose their exclusive rights to manufacture and sell these drugs, which could impact their revenue streams[5].

Licensing and Litigation

The scope and claims of this patent, as well as its expiration, can influence licensing agreements and litigation. Broader claims might lead to more complex licensing negotiations and higher litigation costs, while narrower claims could simplify these processes[3].

Metrics for Measuring Patent Scope

Research has shown that the scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics can help in understanding the breadth and clarity of the patent claims, which in turn can affect the patent's validity and the incentives for innovation[3].

Conclusion

United States Patent 8,785,632 is a critical patent in the field of cancer treatment, focusing on enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Understanding its scope, claims, and the broader patent landscape is essential for pharmaceutical companies, researchers, and policymakers.

Key Takeaways

• Patent Scope: The patent covers specific chemical compounds and their use as c-Met inhibitors.
• Claims: It includes claims for the compounds, their synthesis, and their use in treating cancers.
• Expiration Date: The patent is set to expire on March 1, 2025.
• Impact: The expiration will open the market to generic competitors, affecting competition and pricing.
• Metrics: Independent claim length and count can measure the patent's scope and impact on innovation.

FAQs

Q: What is the main focus of United States Patent 8,785,632? A: The patent focuses on enantiomerically pure aminoheteroaryl compounds as protein tyrosine kinase inhibitors, particularly c-Met inhibitors for cancer treatment.

Q: Who are the assignees of this patent? A: The patent is assigned to Agouron Pharmaceuticals, Inc., and Pfizer Inc.

Q: When is the patent set to expire? A: The patent is scheduled to expire on March 1, 2025.

Q: What are the implications of the patent's expiration? A: The expiration will allow generic versions of the drug to enter the market, potentially reducing costs and increasing accessibility.

Q: How can the scope of a patent be measured? A: The scope can be measured using metrics such as independent claim length and independent claim count.

Sources

1. US8785632B2 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors - Google Patents
2. Generic Xalkori Availability - Drugs.com
3. Patent Claims and Patent Scope - SSRN
4. US8785632B2 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors - Google Patents
5. List - 65 Drug Patents Expiring in 2025 - GreyB

Drugs Protected by US Patent 8,785,632

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-002	Sep 7, 2023		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-003	Sep 7, 2023		RX	Yes	Yes			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No				Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes				Y

International Family Members for US Patent 8,785,632

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1786785		PA2013005	Lithuania
European Patent Office	1786785		CA 2013 00009	Denmark
European Patent Office	1786785		92155	Luxembourg
European Patent Office	1786785		C300587	Netherlands
European Patent Office	1786785		C20130007 00075	Estonia
European Patent Office	1786785		2013/009	Ireland
European Patent Office	1786785		13C0015	France